

Adam S Cheifetz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5272211/publications.pdf>

Version: 2024-02-01

180
papers

7,238
citations

50276

46
h-index

64796

79
g-index

180
all docs

180
docs citations

180
times ranked

7056
citing authors

#	ARTICLE	IF	CITATIONS
1	The Incidence and Management of Infusion Reactions To Infiximab: A Large Center Experience. American Journal of Gastroenterology, 2003, 98, 1315-1324.	0.4	442
2	The Risk of Retention of the Capsule Endoscope in Patients with Known or Suspected Crohn's Disease. American Journal of Gastroenterology, 2006, 101, 2218-2222.	0.4	358
3	Impact of Antibodies to Infiximab on Clinical Outcomes and Serum Infiximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis. American Journal of Gastroenterology, 2013, 108, 40-47.	0.4	298
4	Crohn Disease: Epidemiology, Diagnosis, and Management. Mayo Clinic Proceedings, 2017, 92, 1088-1103.	3.0	292
5	Functional variants in the <i>LRRK2</i> gene confer shared effects on risk for Crohn's disease and Parkinson's disease. Science Translational Medicine, 2018, 10, .	12.4	273
6	Ulcerative Colitis. Mayo Clinic Proceedings, 2014, 89, 1553-1563.	3.0	236
7	Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2019, 17, 1655-1668.e3.	4.4	214
8	Systematic Review and Meta-analysis on the Effects of Thiopurines on Birth Outcomes from Female and Male Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 15-22.	1.9	211
9	Proactive Therapeutic Concentration Monitoring of Infiximab May Improve Outcomes for Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 1996-2003.	1.9	198
10	Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infiximab. Clinical Gastroenterology and Hepatology, 2017, 15, 1580-1588.e3.	4.4	181
11	Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2019, 17, 139-147.	4.4	138
12	Management of Active Crohn Disease. JAMA - Journal of the American Medical Association, 2013, 309, 2150.	7.4	118
13	Complementary and Alternative Medicines Used by Patients With Inflammatory Bowel Diseases. Gastroenterology, 2017, 152, 415-429.e15.	1.3	114
14	Capsule Endoscopy Retention: Is it a Complication?. Journal of Clinical Gastroenterology, 2006, 40, 688-691.	2.2	110
15	Histologic Markers of Inflammation in Patients With Ulcerative Colitis in Clinical Remission. Clinical Gastroenterology and Hepatology, 2013, 11, 991-996.	4.4	109
16	Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials. Clinical Gastroenterology and Hepatology, 2015, 13, 2233-2240.e2.	4.4	109
17	The Burden of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 545-552.	1.9	106
18	Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2019, 13, 976-981.	1.3	104

#	ARTICLE	IF	CITATIONS
19	The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 786-794.	3.7	96
20	Monoclonal antibodies, immunogenicity, and associated infusion reactions. <i>Mount Sinai Journal of Medicine</i> , 2005, 72, 250-6.	1.9	94
21	A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 2014-2025.	0.4	93
22	Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 804-810.	1.3	91
23	Use of anti-TNF drug levels to optimise patient management. <i>Frontline Gastroenterology</i> , 2016, 7, 289-300.	1.8	88
24	Varicella zoster virus infection in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2392-2403.	1.9	87
25	Infliximab in inflammatory bowel disease. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231983844.	2.5	82
26	Meta-analysis of dye-based chromoendoscopy compared with standard- and high-definition white-light endoscopy in patients with inflammatory bowel disease at increased risk of colon cancer. <i>Gastrointestinal Endoscopy</i> , 2019, 90, 186-195.e1.	1.0	80
27	CD39 and CD161 Modulate Th17 Responses in Crohn's Disease. <i>Journal of Immunology</i> , 2014, 193, 3366-3377.	0.8	79
28	Predictors of Endoscopic Inflammation in Patients With Ulcerative Colitis in Clinical Remission. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 779-784.	1.9	71
29	Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 837-848.	3.0	71
30	Cyclosporine is Safe and Effective in Patients With Severe Ulcerative Colitis. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 107-112.	2.2	66
31	Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2266-2271.	1.9	65
32	Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies. <i>Clinical Immunology</i> , 2019, 206, 9-14.	3.2	63
33	Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1510-1515.	1.9	62
34	Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2. <i>Gut</i> , 2007, 56, 1210-1217.	12.1	60
35	Melanin-concentrating hormone as a mediator of intestinal inflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 10613-10618.	7.1	59
36	Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 171-185.	8.1	57

#	ARTICLE	IF	CITATIONS
37	Vitamin D Levels in Adults with Crohn's Disease Are Responsive to Disease Activity and Treatment. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 856-860.	1.9	56
38	Biologic Concentration Testing in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	1.9	56
39	Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 3067-3073.	2.3	54
40	Characterization of Human CD39+ Th17 Cells with Suppressor Activity and Modulation in Inflammatory Bowel Disease. <i>PLoS ONE</i> , 2014, 9, e87956.	2.5	54
41	Capsule endoscopy for small-bowel evaluation in Crohn's disease. <i>Gastrointestinal Endoscopy</i> , 2011, 74, 167-175.	1.0	51
42	In Vitro Fertilization Is Successful in Women With Ulcerative Colitis and Ileal Pouch Anal Anastomosis. <i>American Journal of Gastroenterology</i> , 2015, 110, 792-797.	0.4	51
43	A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF. <i>Gastroenterology</i> , 2016, 151, 710-723.e2.	1.3	51
44	CD39 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease. <i>European Journal of Immunology</i> , 2012, 42, 3062-3072.	2.9	50
45	Therapeutic Drug Monitoring in IBD: The New Standard-of-Care for Anti-TNF Therapy. <i>American Journal of Gastroenterology</i> , 2017, 112, 673-676.	0.4	50
46	The Diagnosis and Treatment of Pouchitis in Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2004, 38, S44-S50.	2.2	49
47	Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1057-1063.	1.9	48
48	Meta-analysis of Virtual-based Chromoendoscopy Compared With Dye-spraying Chromoendoscopy Standard and High-definition White Light Endoscopy in Patients With Inflammatory Bowel Disease at Increased Risk of Colon Cancer. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1319-1329.	1.9	48
49	The Appropriateness of Concomitant Immunomodulators With Anti-Tumor Necrosis Factor Agents for Crohn's Disease: One Size Does Not Fit All. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 655-659.	4.4	46
50	Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2806-2814.	1.9	46
51	Factors that Affect Adherence to Surveillance Colonoscopy in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 534-539.	1.9	45
52	Abdominal phlegmons in Crohn's disease: Outcomes following antitumor necrosis factor therapy. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 691-696.	1.9	42
53	Therapeutic drug monitoring in inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2019, 35, 302-310.	2.3	42
54	Review article: emerging drug therapies in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 789-804.	3.7	38

#	ARTICLE	IF	CITATIONS
55	Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1608-1616.	1.9	36
56	Systematic Analysis Underlying the Quality of the Scientific Evidence and Conflicts of Interest in Interventional Medicine Subspecialty Guidelines. <i>Mayo Clinic Proceedings</i> , 2014, 89, 16-24.	3.0	36
57	Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1302-1309.	4.4	36
58	The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 427-435.	1.9	36
59	Miscellaneous Adverse Events with Biologic Agents (Excludes Infection and Malignancy). <i>Gastroenterology Clinics of North America</i> , 2014, 43, 543-563.	2.2	35
60	Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: A Cost-Effectiveness Analysis in a Simulated Cohort. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 103-111.	1.9	34
61	Poor Documentation of Inflammatory Bowel Disease Quality Measures in Academic, Community, and Private Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 421-428.e2.	4.4	33
62	Indications for Mode of Delivery in Pregnant Women with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 721-726.	1.9	33
63	A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 191-197.	1.9	33
64	Failure to Induce Oral Tolerance in Crohn's and Ulcerative Colitis Patients: Possible Genetic Risk. <i>Annals of the New York Academy of Sciences</i> , 2004, 1029, 225-238.	3.8	31
65	Evidence for a genetic defect in oral tolerance induction in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 82-88.	1.9	31
66	Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1007-1014.	0.4	31
67	Infliximab: Use in inflammatory bowel disease. <i>Current Treatment Options in Gastroenterology</i> , 2005, 8, 187-196.	0.8	30
68	Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis: A prospective study. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 171-175.	1.3	30
69	Herpes Zoster Vaccine Response in Inflammatory Bowel Disease Patients on Low-dose Immunosuppression. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1391-1396.	1.9	29
70	The Role of Mucosal Healing in the Treatment of Patients With Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , 2014, 12, 103-117.	0.8	28
71	In Vitro Fertilization in Women With Inflammatory Bowel Disease Is as Successful as in Women From the General Infertility Population. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1641-1646.e3.	4.4	28
72	Management of acute severe ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 395-405.	3.0	25

#	ARTICLE	IF	CITATIONS
73	Meta-Analysis of the Placebo Response in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2008, 53, 875-891.	2.3	23
74	Systematic Analysis Underlying the Quality of the Scientific Evidence and Conflicts of Interest in Gastroenterology Practice Guidelines. <i>American Journal of Gastroenterology</i> , 2013, 108, 1686-1693.	0.4	23
75	Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis. <i>Annals of Gastroenterology</i> , 2016, 29, 341-7.	0.6	23
76	Efficacy and Safety of Natalizumab in Crohn's Disease Patients Treated at 6 Boston Academic Hospitals. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2457-2463.	1.9	22
77	Attitudes to Mesalamine Questionnaire: A Novel Tool to Predict Mesalamine Nonadherence in Patients with IBD. <i>American Journal of Gastroenterology</i> , 2014, 109, 1850-1855.	0.4	21
78	Surgery for Ulcerative Colitis Is Associated with a High Rate of Readmissions at 30 Days. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2130-2136.	1.9	21
79	Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1418-1424.	1.9	21
80	Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 761-767.	2.3	21
81	Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?. <i>Gastroenterology</i> , 2018, 154, 1201-1202.	1.3	20
82	Documented Compliance with Inflammatory Bowel Disease Quality Measures Is Poor. <i>Digestive Diseases and Sciences</i> , 2015, 60, 339-344.	2.3	19
83	Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology. <i>Current Opinion in Rheumatology</i> , 2020, 32, 371-379.	4.3	19
84	Impact of Concomitant Immunomodulator Use on Long-Term Outcomes in Patients Receiving Scheduled Maintenance Infliximab. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1413-1420.	2.3	18
85	<i>Mycobacterium marinum</i> : An Increasingly Common Opportunistic Infection in Patients on Infliximab. <i>American Journal of Gastroenterology</i> , 2012, 107, 1268-1269.	0.4	18
86	Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2873-2878.	1.9	18
87	Systematic analysis of the quality of the scientific evidence and conflicts of interest in osteoarthritis of the hip and knee practice guidelines. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 379-385.	3.4	18
88	Prevalence and Lifetime Risk of Endoscopy-related Complications Among Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1288-1293.	4.4	17
89	Expression of Ecto-nucleoside Triphosphate Diphosphohydrolases-2 and -3 in the Enteric Nervous System Affects Inflammation in Experimental Colitis and Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1113-1123.	1.3	17
90	Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 3142.	2.4	17

#	ARTICLE	IF	CITATIONS
91	Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 465-467.e2.	4.4	17
92	Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). <i>BMJ Open</i> , 2022, 12, e057656.	1.9	17
93	Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg ⁻) on anti-TNF therapy have a low rate of reactivation. <i>Clinical Immunology</i> , 2018, 191, 59-62.	3.2	16
94	Endogenous antisense RNA curbs CD39 expression in Crohn's disease. <i>Nature Communications</i> , 2020, 11, 5894.	12.8	16
95	Utility of CT in the Emergency Department in Patients with Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 793-800.	1.9	15
96	Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 839-841.e2.	4.4	15
97	Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2019, 15, 656-665.	0.1	15
98	Anti-Tumour Necrosis Factor Therapy for Ulcerative Colitis. <i>Drugs</i> , 2006, 66, 2059-2065.	10.9	14
99	Systematic Analysis and Critical Appraisal of the Quality of the Scientific Evidence and Conflicts of Interest in Practice Guidelines (2005-2013) for Barrett's Esophagus. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2812-2822.	2.3	13
100	Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e143-e145.	1.9	13
101	The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 998-1005.	1.9	13
102	High Self-efficacy Predicts Adherence to Surveillance Colonoscopy in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1602-1610.	1.9	12
103	Immune-mediated Reactions to Anti-tumor Necrosis Factors in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1176-1186.	1.9	12
104	Factors Associated with the Success of In Vitro Fertilization in Women with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2381-2388.	2.3	12
105	Doctor Message Can Alter Patients' Behavior and Attitudes Regarding Inflammatory Bowel Disease and Colon Cancer. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1531-1539.	1.9	11
106	The Use of Complementary and Alternative Medicine in Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2018, 14, 415-425.	0.1	11
107	Setting priorities for comparative effectiveness research in inflammatory bowel disease: Results of an international provider survey, expert rand panel, and patient focus groups. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2294-2300.	1.9	10
108	Characteristics of Inflammatory Bowel Disease Serology in Patients With Indeterminate Colitis. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 351-355.	2.2	10

#	ARTICLE	IF	CITATIONS
109	Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 507-509.	1.3	10
110	Identifying IBD Providers' Knowledge Gaps Using a Prospective Web-based Survey. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1445-1450.	1.9	10
111	Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy. <i>World Journal of Gastroenterology</i> , 2017, 23, 6197.	3.3	10
112	Targeted Physician Education and Standardizing Documentation Improves Documented Reporting with Inflammatory Bowel Disease Quality Measures in a Large Academic and Private Practice. <i>Digestive Diseases and Sciences</i> , 2018, 63, 36-45.	2.3	9
113	Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1129-1135.	0.9	8
114	Therapeutic Drug Monitoring of Biologics in Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2022, 51, 299-317.	2.2	8
115	Reducing the Torment of Diarrhea. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 797-798.	2.2	7
116	Bone of Contention: <i>Helicobacter pylori</i> and Osteoporosis—Is There an Association?. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2736-2739.	2.3	7
117	The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1217-1226.	1.3	7
118	Evaluation of the small bowel in inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 239-251.	3.0	6
119	A rare case series of concomitant inflammatory bowel disease, sporadic adenomas, and serrated polyposis syndrome. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1735-1739.	1.3	6
120	New role for azathioprine in case of switching anti-TNFs in IBD. <i>Gut</i> , 2020, 69, 1165-1167.	12.1	6
121	Review of Societal Recommendations Regarding Management of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 940-946.	1.9	6
122	Thyroid cancer and Crohn's disease: Association or coincidence?. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 79-80.	1.9	5
123	Is It Prime Time for Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease?. <i>Gastroenterology</i> , 2019, 157, 922-924.	1.3	5
124	Health Maintenance Consensus for Adults With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1552-1563.	1.9	5
125	Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 1423-1431.	3.3	5
126	Varicella zoster meningoradiculitis in Crohn's disease treated with 6-mercaptopurine. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E109-E110.	1.9	4

#	ARTICLE	IF	CITATIONS
127	Utility of Emergency Department Use of Abdominal Pelvic Computed Tomography in the Management of Crohn's Disease. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 859-864.	2.2	4
128	How to Develop the Medical Neighborhood. <i>Journal of Medical Systems</i> , 2016, 40, 196.	3.6	4
129	Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit All. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1829-1831.	4.4	4
130	Varicella zoster virus infection in patients with inflammatory bowel disease. <i>Gastroenterology and Hepatology</i> , 2013, 9, 56-8.	0.1	4
131	Overview of Therapeutic Drug Monitoring of Biologic Agents in Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2017, 13, 556-559.	0.1	4
132	Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient. <i>Journal of Clinical Medicine</i> , 2021, 10, 5642.	2.4	4
133	Proactive Therapeutic Drug Monitoring of Adalimumab in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2023, 164, 164-165.	1.3	4
134	Infliximab decreases colectomy rates in moderate to severe ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1626-1628.	1.9	3
135	Cryptosporidiosis masquerading as a Crohn's flare. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E133-E134.	1.9	3
136	It Is Time to Treat to Trough: Staying Ahead of the Curve in Biologic Testing. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2384.	4.4	3
137	Histological healing beyond endoscopic healing in ulcerative colitis: Shall we target the "ultra-deep" remission?. <i>Digestive and Liver Disease</i> , 2017, 49, 1332-1333.	0.9	3
138	De-escalating medical therapy in Crohn's disease patients who are in deep remission: A RAND appropriateness panel. <i>GastroHep</i> , 2019, 1, 108-117.	0.6	3
139	Proactive Adalimumab Monitoring in Inflammatory Bowel Disease: Current Data and Future Perspectives. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 878-879.	1.3	3
140	A Survey Study of Gastroenterologists' Views on Dysplasia Surveillance and Chromoendoscopy in IBD. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e59-e61.	1.9	3
141	Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 854-855.	4.4	3
142	Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case Series. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	2.3	3
143	Choosing the right biologic for complications of inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 235-249.	3.0	3
144	Response to Dr. Spada and Colleagues. <i>American Journal of Gastroenterology</i> , 2007, 102, 1543-1544.	0.4	2

#	ARTICLE	IF	CITATIONS
145	Infusion Reactions Related to Infliximab Therapy Are Not Usually Associated with Drug Discontinuation. <i>Journal of Rheumatology</i> , 2012, 39, 1500-1502.	2.0	2
146	P-084 Self-Reported Health Maintenance Behaviors in a Population of Patients with Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, S58-S59.	1.9	2
147	Inflammatory Bowel Disease-Related Abstracts Presented at National Conferences in the USA Are Frequently Unpublished as Full Manuscripts. <i>Digestive Diseases and Sciences</i> , 2017, 62, 352-357.	2.3	2
148	C-reactive protein as a predictor of low trough infliximab concentrations in patients who lose response to infliximab. <i>Journal of Digestive Diseases</i> , 2017, 18, 678-683.	1.5	2
149	Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease" results from the ENEIDA registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 599-600.	3.7	2
150	Tu1830 " Influximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients with Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2019, 156, S-1141.	1.3	2
151	Evidence Supporting High-Dose Use of Biologics in Clinical Practice. <i>Current Treatment Options in Gastroenterology</i> , 2020, 18, 408-422.	0.8	2
152	Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay. <i>Journal of Clinical Medicine</i> , 2020, 9, 2840.	2.4	2
153	Editorial: is there a role for monitoring intermediate anti-TNF drug concentrations in IBD?. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1049-1050.	3.7	2
154	Assessing the repercussions of COVID-19 pandemic on symptoms, disease management, and emotional well-being in patients with inflammatory bowel disease: a multi-site survey study. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 406-414.	1.5	2
155	PUCCINI: Safety of Anti-TNF in the Perioperative Setting. <i>Gastroenterology</i> , 2022, 163, 44-46.	1.3	2
156	Targeting TNF in postoperative recurrence of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1925-1926.	1.9	1
157	Vaccination in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2011, 106, 168.	0.4	1
158	Lectin-reactive Anti-Î±-Gal in Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2796-2800.	1.9	1
159	Editorial: therapeutic de-escalation of anti-tumour necrosis factor therapy " is less enough?. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1265-1266.	3.7	1
160	Response. <i>Gastrointestinal Endoscopy</i> , 2020, 91, 719-720.	1.0	1
161	Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1085-1086.	3.7	1
162	Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1067.	7.4	1

#	ARTICLE	IF	CITATIONS
163	You Say Goodbye and I Say Aloe. , 2004, 10, 693-695.		0
164	Comparative effectiveness research in inflammatory bowel disease: prospects and challenges. Expert Review of Gastroenterology and Hepatology, 2012, 6, 405-407.	3.0	0
165	Commentary: irritable bowel syndrome and the <scp>CDAI</scp> â€“ misleading activity by straw men; authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2013, 37, 1021-1022.	3.7	0
166	Crohn Disease. JAMA - Journal of the American Medical Association, 2014, 312, 1708.	7.4	0
167	Colonoscopy Is Appropriately Utilized In Most Cases Following a Fair Bowel Prep. American Journal of Gastroenterology, 2014, 109, 1289.	0.4	0
168	In replyâ€“Clinical Practice Guidelines: Still Miles to Goâ€ . Mayo Clinic Proceedings, 2014, 89, 860-861.	3.0	0
169	Reply to Use of CT Scan in Ulcerative Colitis Patients Presenting to the Emergency Department. Inflammatory Bowel Diseases, 2015, 21, E21.	1.9	0
170	Reply. Clinical Gastroenterology and Hepatology, 2017, 15, 1638-1639.	4.4	0
171	Response to Reinink. American Journal of Gastroenterology, 2017, 112, 1893-1894.	0.4	0
172	Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 465-466.	1.9	0
173	Editorial: early postâ€induction antiâ€<scp>TNF</scp> drug monitoring can predict longâ€term therapeutic outcomes in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2018, 47, 436-437.	3.7	0
174	Reply. Clinical Gastroenterology and Hepatology, 2018, 16, 598-599.	4.4	0
175	Integrin Calculus: The Predictive Power of Vedolizumab Concentrations in IBD Therapy. Digestive Diseases and Sciences, 2019, 64, 1397-1398.	2.3	0
176	The cost and benefit of anti-TNF therapy from a population perspectiveâ€”for what itâ€™s worth. Annals of Translational Medicine, 2019, 7, S388-S388.	1.7	0
177	Cannabis and Inflammatory Bowel Disease: All Smoke and Mirrors?. Journal of Crohn's and Colitis, 2021, 15, 1785-1786.	1.3	0
178	Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGE Group. Gastroenterology and Hepatology, 2008, 4, 713-20.	0.1	0
179	Appropriateness of Medical and Surgical Treatments for Chronic Pouchitis Using RAND/UCLA Appropriateness Methodology. Digestive Diseases and Sciences, 2022, , 1.	2.3	0
180	Letter: is blindly stopping thiopurines without confirming adequate <scp>antiâ€TNF</scp> concentrations shortsighted?. Alimentary Pharmacology and Therapeutics, 2022, 55, 887-888.	3.7	0